1. Home
  2. ARTL vs SLRX Comparison

ARTL vs SLRX Comparison

Compare ARTL & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$1.84

Market Cap

3.4M

Sector

Health Care

ML Signal

HOLD

Logo Salarius Pharmaceuticals Inc.

SLRX

Salarius Pharmaceuticals Inc.

HOLD

Current Price

$0.86

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARTL
SLRX
Founded
2011
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4M
3.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ARTL
SLRX
Price
$1.84
$0.86
Analyst Decision
Buy
Analyst Count
3
0
Target Price
$30.00
N/A
AVG Volume (30 Days)
1.3M
5.1M
Earning Date
11-12-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.52
$0.71
52 Week High
$28.60
$108.00

Technical Indicators

Market Signals
Indicator
ARTL
SLRX
Relative Strength Index (RSI) 33.96 25.79
Support Level $1.62 $0.85
Resistance Level $1.98 $0.97
Average True Range (ATR) 0.19 0.11
MACD 0.11 0.07
Stochastic Oscillator 69.53 25.70

Price Performance

Historical Comparison
ARTL
SLRX

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About SLRX Salarius Pharmaceuticals Inc.

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Share on Social Networks: